Partial Inhibition of Calcineurin Activity by Rcn2 as a Potential Remedy for Vps13 Deficiency by Wardaszka, Patrycja et al.
 International Journal of 
Molecular Sciences
Article
Partial Inhibition of Calcineurin Activity by Rcn2 as a Potential
Remedy for Vps13 Deficiency
Patrycja Wardaszka , Piotr Soczewka, Marzena Sienko , Teresa Zoladek and Joanna Kaminska *


Citation: Wardaszka, P.; Soczewka,
P.; Sienko, M.; Zoladek, T.; Kaminska,
J. Partial Inhibition of Calcineurin
Activity by Rcn2 as a Potential
Remedy for Vps13 Deficiency. Int. J.
Mol. Sci. 2021, 22, 1193. https://
doi.org/10.3390/ijms22031193
Academic Editor: Toshio Ohshima
Received: 7 October 2020
Accepted: 22 January 2021
Published: 26 January 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
Institute of Biochemistry and Biophysics Polish Academy of Science, 02-106 Warsaw, Poland;
patrycja@ibb.waw.pl (P.W.); psoc@ibb.waw.pl (P.S.); marsi@ibb.waw.pl (M.S.); teresa@ibb.waw.pl (T.Z.)
* Correspondence: kaminska@ibb.waw.pl; Tel.: +48-22-592-1316
Abstract: Regulation of calcineurin, a Ca2+/calmodulin-regulated phosphatase, is important for
the nervous system, and its abnormal activity is associated with various pathologies, including
neurodegenerative disorders. In yeast cells lacking the VPS13 gene (vps13∆), a model of VPS13-linked
neurological diseases, we recently demonstrated that calcineurin is activated, and its downregulation
reduces the negative effects associated with vps13∆ mutation. Here, we show that overexpression of
the RCN2 gene, which encodes a negative regulator of calcineurin, is beneficial for vps13∆ cells. We
studied the molecular mechanism underlying this effect through site-directed mutagenesis of RCN2.
The interaction of the resulting Rcn2 variants with a MAPK kinase, Slt2, and subunits of calcineurin
was tested. We show that Rcn2 binds preferentially to Cmp2, one of two alternative catalytic subunits
of calcineurin, and partially inhibits calcineurin. Rcn2 ability to bind to and reduce the activity of
calcineurin was important for the suppression. The binding of Rcn2 to Cmp2 requires two motifs in
Rcn2: the previously characterized C-terminal motif and a new N-terminal motif that was discovered
in this study. Altogether, our findings can help to better understand calcineurin regulation and to
develop new therapeutic strategies against neurodegenerative diseases based on modulation of the
activity of selected calcineurin isoforms.
Keywords: neurodegenerative diseases; calcium signaling; calcineurin; yeast model; Vps13; Rcn2
1. Introduction
Calcium ions (Ca2+) are important signaling molecules that regulate multiple pro-
cesses. In neurons, calcium signaling is crucial for neurotransmitter release and for trigger-
ing a wide range of changes in neuronal function. Among the different proteins involved
are Ca2+ sensors that transduce signals to specific effectors in a cell. One of the best-studied
Ca2+-responsive signaling pathways involves a Ca2+/calmodulin-dependent protein phos-
phatase, calcineurin, which is also known to be important for the immune response [1].
Calcineurin is present in virtually all organisms. The architecture of this phosphatase,
which is composed of catalytic and regulatory subunits, is conserved among species. In
human cells, there are three different isoforms of the catalytic subunit (α, β, and γ, encoded
by PPP3CA, PPP3CB, and PPP3CC genes, respectively) and two regulatory subunits (B1
and B2, encoded by PPP3R1 and PPP3R2 genes, respectively) [2,3]. The activity of cal-
cineurin must be tightly regulated because its abnormal activity is associated with various
pathologies in humans, including neurological and psychological disorders [4]. Therefore,
calcineurin exists in an autoinhibited state and is activated when Ca2+ concentration is
increased, and Ca2+/calmodulin is bound [5]. Thus, calcineurin inhibition may occur
through Ca2+ or calmodulin sequestration or, alternatively, by blocking the binding of
calmodulin to substrates or activators. The calcineurin recognizes two types of linear
motifs in its substrates and regulators, PxIxIT and LxVP, by two binding pockets—one
for each motif. PxIxIT-type motif recognition is independent of the presence of the reg-
ulatory subunit. The LxVP-type motif binds at the junction of catalytic and regulatory
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subunits [6]. Thus, blocking the pocket responsible for PxIxIT-type motif binding pre-
vents the interaction of calcineurin with substrates that possess this type of motif without
blocking calcineurin activity. By contrast, blocking the binding site for the LxVP-type
motif not only interferes with substrate binding but also inhibits calcineurin activity. This
site is also used by the immunosuppressants FK506 and cyclosporin A, which block sub-
strate binding to the active p site of phosphatase [6]. They are common in medical use,
although they have serious side effects [7,8]. There is a group of proteins, known as the
regulators of calcineurin (RCANs) [9], that inhibit phosphatase activity by occupying
substrate-binding motifs. In human cells, there are three RCAN-encoding genes, RCAN1
(DSCR1/CALP1/MCIP1/ADAPT78), RCAN2 (DSCR1L1/CALP2/ZAKI-4/MCIP2), and RCAN3
(DSCR1L2⁄CALP3⁄MCIP3) [10,11]. The most prominent feature identified in RCAN family
proteins is a serine–proline motif (containing an ISPPXSPP box), which is conserved across
species [9]. Moreover, at the N-terminus, weak homology with RNA-binding domains has
been detected [10] and, recently, it was shown that this region of RCAN1 binds to RNA [12].
The human RCAN1 gene has potential roles in Down syndrome, Alzheimer’s disease, in
the regulation of the immune and inflammatory responses, and in different types of patho-
logical angiogenesis [13]. All mammalian RCANs are expressed in the brain [10,13,14]
and are important for brain physiology [15]. Furthermore, calcineurin catalytic subunits
are specifically regulated by posttranslational modifications such as phosphorylation or
ubiquitination [16,17].
In yeast cells, two alternative catalytic subunits of calcineurin are encoded by either
CNA1 or CMP2/CNA2 genes [18], and only one regulatory subunit is encoded by CNB1 [19].
There are also two RCANs: Rcn1 and Rcn2. The RCN2 gene that encodes the Rcn2 protein
was identified in a genetic screen for endogenous inhibitors of calcineurin [20]. Rcn2 shares
structural and functional similarities to Rcn1 and RCAN proteins in other yeasts and is
more distantly related to RCANs in mammals [9]. Active calcineurin dephosphorylates
numerous factors that promote cell survival. In yeast, the best-investigated example is the
transcription factor Crz1 [21], which is regulated similarly to the NFAT (nuclear factor of
activated T cells) transcription factor in mammalian cells [6,22]. Furthermore, calcineurin
inhibits a plasma membrane Ca2+ channel and a vacuolar H+/Ca2+ exchanger, both of
which participate in the control cytosolic Ca2+ levels [23]. In yeast cells, proper regulation of
calcineurin is important for the response to environmental stress, during which cytoplasmic
Ca2+ levels are increased and for survival during long-term endoplasmic reticulum (ER)
stress [24–27]. However, calcineurin is not important under standard growth conditions but
becomes essential in cells lacking certain proteins involved in the maintenance of cell wall
integrity, such as Slt2, Fks1, or Pkc1 [28]. Calcineurin activity is upregulated in yeast models
of neurodegenerative diseases, including Parkinson’s disease [29]. Recently, we showed
that calcineurin activity is increased in a yeast mutant lacking the Vps13 protein [30],
indicating the link of Vps13 with calcium signaling.
The human genome contains four VPS13 genes, hVPS13A-D, which encode proteins
associated with the neurological disorders: chorea-acanthocytosis (ChAc) [31], Cohen
syndrome [32], early-onset Parkinsonism [33], and spastic ataxia and paraplegia [34,35], re-
spectively. VPS13 genes are conserved among eukaryotes, and proteins of the Vps13 family
show the highest homology in the N- and C-termini [36]. Vps13 proteins are proposed to be
lipid transfer proteins based on in vitro studies showing that the N-terminus of yeast Vps13
is able to transfer lipids between liposomes [37]. This is also supported by a structural
study of the N-terminal part of the Vps13 protein from Chaetomium thermophilum [38]. The
high homology of the N-terminal part of all Vps13 proteins [36] suggests that they have a
common function. However, the phenotypes caused by their dysfunction differ, which is
indicative of differences in their regulation and/or localization. Indeed, differences in the
localization of hVps13A and hVps13C proteins to membrane contact sites (MCS) have been
described [37]. In yeast cells, the Vps13 protein localizes to various MCSs depending on the
growth conditions [39–41]. Therefore, the localization of Vps13 proteins must be regulated
by certain signals. Recently, it has been reported that the APT1 domains of hVps13A
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and yeast Vps13 bind signaling phosphoinositides and that this binding is differentially
regulated by Ca2+ [42].
Noteworthy, a decrease in the level of Orai1 protein, the subunit of a channel re-
sponsible for Ca2+ entry into the cell, was found in fibroblasts of ChAc patients, resulting
in a decrease in the influx of Ca2+ ions [43,44]. However, the synaptic hyperexcitability
observed in ChAc neurons is not linked to changes in Ca2+ signaling but to changes in actin
polymerization since actin influences the release of synaptic neurotransmitters [45]. More
information about the function and regulation of Vps13 proteins, and the consequences of
their defect, can be obtained using simple model organisms, such as yeast [46].
Since yeast cells have only one VPS13 gene, which encodes a protein similar to all
human Vps13 proteins, yeast can be used to study the effect of human VPS13 gene muta-
tions on cell physiology. This has already been successfully carried out to study the effect
of mutations in hVPS13A and hVPS13D genes in terms of human diseases [30,40,47,48].
Recently, we demonstrated that in yeast cells lacking the VPS13 gene (vps13∆), the phos-
phorylation of MAPK kinase, the Slt2 protein, is increased and that calcium signaling is
activated [30]. Moreover, we indicated that downregulation of this activity by Ca2+ chela-
tion, administration of FK506, or calmodulin sequestration could mitigate the negative
effects of vps13∆ mutation [30]. A more comprehensive understanding of the components,
functions, and molecular mechanism of the Ca2+/calcineurin signaling cascade in yeast
models of diseases will provide insights into pathological interactions and facilitate the
development of novel therapeutic approaches.
In this work, we show that overexpression of the RCN2 gene, which encodes a negative
regulator of calcineurin, is beneficial for vps13∆ mutant cells, and we studied the molecular
mechanisms underlying RCN2 action. The results of site-directed mutagenesis, two-hybrid
interaction studies, and phenotypic analysis show that suppression does not involve the
interaction of Rcn2 protein with Slt2 kinase but involves binding with one of the calcineurin
catalytic subunits, the Cmp2 protein. These results demonstrate that effective suppression
of vps13 mutant phenotypes can be obtained by inhibiting a subset of calcineurin complexes
containing a particular isoform of a catalytic subunit, and this finding could be used in the
development of new strategies to treat numerous neurodegenerative diseases.
2. Results
2.1. The RCN2 Gene is a Multicopy Suppressor of vps13∆ SDS Hypersensitivity
A vps13 mutants exhibit several phenotypes: they show defects in protein trans-
port [49–51], sporulation [52], and actin cytoskeleton organization [47]. Our studies in-
dicate the alteration of calcium homeostasis in vps13∆ cells and a functional connection
between Vps13 and calcium signaling [30]. To this list, we recently added a new phenotype:
hypersensitivity to low concentrations of a commonly used amphiphilic detergent, sodium
dodecyl sulfate (SDS), which we used in a genetic screen for multicopy suppressors of
the vps13-I2749R mutation. This screen resulted in the identification of fragments of the
MYO3 gene (MYO3-N) and of the FET4 gene [30,53] as suppressors, and both were also
effective in vps13∆ cells. In this screen, we also found that a plasmid containing the RCN2
gene, which encodes a negative regulator of calcineurin, restored the growth of the vps13∆
mutant in the presence of SDS (Figure 1). The paralogous RCN1 gene, which encodes the
other calcineurin regulator, has not been isolated; thus, we directly tested whether the
overexpression of RCN1 [54] could restore the growth of vps13∆ cells on SDS medium. In
contrast to RCN2, overexpressed RCN1 was not active as a suppressor (Figure 1). These
results support the view that specific downregulation of calcium signaling, including that
caused by Rcn2, is beneficial for vps13∆ mutant cells.
Int. J. Mol. Sci. 2021, 22, 1193 4 of 17
Figure 1. RCN2, but not RCN1, is a multicopy suppressor of the sodium dodecyl sulfate (SDS)
hypersensitivity phenotype of the vps13∆ mutant. Serial dilutions of wild-type and vps13∆ strains
transformed with empty vector [-] or vector bearing RCN2 or RCN1 genes were plated on YPD and
YPD + SDS media. Plates were incubated for 3 days.
2.2. Binding of Rcn2 to Slt2 Kinase is Not Important for Suppression
Due to the fact that Rcn2 is a substrate of Slt2 kinase [55] and that the vps13∆ mutant
shows increased Slt2 activity upon SDS treatment [30], we speculated that the mechanism
of suppression could rely on Rcn2–Slt2-binding and Rcn2 phosphorylation. To test this
hypothesis, we evaluated the importance of Rcn2 interaction with Slt2 and specifically of
serine amino acid residue (aa) S255, which is phosphorylated by Slt2 [55], in the RCN2-
based suppression of vps13∆. The consensus of the motif recognized by Slt2 kinase in
its target proteins is (R/K)1−2 − (X)2−6 − Φ − X − Φ), where X denotes any aa and Φ
denotes a hydrophobic aa [56]. There are three such motifs in Rcn2, which are potential
Slt2-binding sites (Figure 2a). We analyzed the effects of rcn2-m1, -m2 and -m3 mutations,
each of which causes 3–4 aa substitutions for alanine (Figure 2a). The interaction between
Slt2 and wild-type or mutant Rcn2 proteins was tested using a two-hybrid system. As
shown in Figure 2b, the co-expression of RCN2 and SLT2 resulted in restored growth on
media without leucine, tryptophan and histidine, indicating the interaction of wild-type
Rcn2 protein with Slt2, while the interaction was lost between Rcn2-m2 and Slt2. These
substitutions did not result in the lack of expression of BD-rcn2-m2 (Figure S1). This shows
that aa substitutions in the Rcn2-m2 protein are in the region important for Slt2-binding.
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Figure 2. Rcn2-binding to Slt2 is not important for suppression of vps13∆ SDS hypersensitivity, in
contrast to serine residue S255 and the motif at the N-terminus of Rcn2. (a) Schematic representation
of Rcn2 indicating three potential Slt2-binding sites. Amino acid residues substituted in mutant
proteins, Rcn2-m1, Rcn2-m2, Rcn2-m3, and Rcn2-S255A, are in red. S255 is underlined. (b) Rcn2 and
Slt2 interact in the two-hybrid system. (c) Rcn2-m2 does not interact with Slt2. BD, DNA-binding
domain; AD, activating domain; 3AT, 3-aminotriazole. rcn2-m1 (d) and rcn2-S255A (e) are not able
to suppress the hypersensitivity of vps13∆ to SDS. Serial dilution of wild-type and vps13∆ strains
transformed with empty vector [-] or vector bearing the RCN2 gene were plated on YPD and YPD +
SDS. Plates were incubated for 3 days. (f) rcn2-m1 is less efficiently expressed. Western blot analysis
of HA-Rcn2 and HA-Rcn2-m1, -m2 and -m3 levels in wild-type and vps13∆ mutant cells. The tagged
versions of Rcn2 were detected with the anti-HA antibody. The levels of vacuolar protein Vma2 were
used as a loading control.
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The mutation causing substitution of the S255 residue, which is phosphorylated by
Slt2, for alanine was previously shown to result in the greatest reduction in Rcn2 phos-
phorylation [55]. This mutation was, therefore, introduced into RCN2 (Figure 2a). In the
next step, we tested how all introduced mutations affect the RCN2-based suppression of
vps13∆ SDS hypersensitivity. The rcn2-m2 and rcn2-m3 alleles were effective as suppressors
(Figure 2d), although the protein encoded by rcn2-m2 was not able to bind Slt2 (Figure 2c).
By contrast, the rcn2-m1 and rcn2-S255A alleles (Figure 2d,e) lost the ability to support
the growth of the vps13∆ mutant when overexpressed. This result could be explained by
the introduction of rcn2-m mutations causing instability of the mutant protein or abolish-
ing Rcn2 function in a way that is important for its suppressor activity. To distinguish
between these two possibilities, the cellular levels of hemagglutinin (HA)-tagged versions
of wild-type and mutant Rcn2 proteins were compared. Previous studies of the rcn2-S255A
mutation found that it did not affect the level of the Rcn2 protein, so this was not tested in
our study [55]. As shown in Figure 2f, the HA-Rcn2 protein migrated as multiple bands,
ranging from about 37 to 55 kDa, even though the estimated molecular mass of the tagged
version is about 32.5 kDa. The tagged version HA-Rcn2 is probably not functional because
its overproduction did not reverse the SDS sensitivity of the vps13∆ mutant (Figure S2).
The observed slower migrating bands could include forms that are post-translationally
modified (phosphorylated, ubiquitinated) to mark HA-Rcn2 for degradation. The Western
blot analysis revealed that the HA-Rcn2-m1 protein is produced but at a low level. In
the case of HA-Rcn2-m2, the pattern of bands was slightly different compared with that
of HA-Rcn2 and HA-Rcn-m3. Thus, it is possible that a lack of Slt2-binding affects Rcn2
phosphorylation and/or other posttranslational modifications. The level and modification
pattern of the HA-Rcn2-m3 protein were similar to those of HA-Rcn2. These results in-
dicate that HA-Rcn2 is a highly modified protein and that the N-terminal part of Rcn2 is
important for its stability and functionality. In summary, these results show that the lack
of interaction between Slt2 and Rcn2 does not interfere with the suppression of vps13∆
mutant phenotypes, but the presence of the S255 residue and, therefore, phosphorylation
of this residue is necessary. The inability of rcn2-m1 to suppress vps13∆ could be due to a
low level of Rcn2-m1, but it is also possible that the N-terminal motif of Rcn2 containing
isoleucine residues I10 and I12 is specifically important.
Since the mechanism of suppression is not based on Slt2–Rcn2 interaction, we consid-
ered the second possibility that Rcn2 acts as a negative regulator of calcineurin and that
downregulation of this phosphatase activity is the basis for suppression.
2.3. The Suppression of vps13∆ by RCN2 Requires Calcineurin
RCANs are also involved in calcineurin-independent processes, such as binding
mRNA and affecting its stability [12,13], so we tested whether Rcn2-based suppression
requires calcineurin presence and/or activity. For this reason, the double mutants cnb1∆
vps13∆, cna1∆ vps13∆, and cmp2∆ vps13∆ were constructed that lacked either a regulatory
(Cnb1) or catalytic (Cna1 or Cmp2) subunit. These mutants were transformed with an
RCN2-bearing plasmid, and their growth on SDS-containing media was tested. The double
cnb1∆ vps13∆ mutant was hypersensitive to SDS, and RCN2 overexpression did not cause
suppression (Figure 3a). Similarly, in the cna1∆ vps13∆ double mutant, there was no RCN2-
based suppression (Figure 3b). Because the phosphatase is inactive in the cnb1∆ strain [19],
the lack of suppression in the cnb1∆ vps13∆ mutant indicates that functional calcineurin is
required. Interestingly, the cmp2∆ mutation caused cells not to be SDS-sensitive, and the
double mutant cmp2∆ vps13∆ grew as single cmp2∆ (Figure 3c). Thus, the cmp2∆ mutation
is epistatic to vps13∆. Altogether, these results indicate that in the presence of SDS stress,
the vps13∆ mutation triggers changes in the cell that can be overcome by the reduction of
Cmp2 activity. This could be obtained by RCN2 overexpression or deletion of the CMP2
gene, but the active Cna1–Cnb1 phosphatase complexes are required.
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Figure 3. The suppression of vps13∆ mutant SDS hypersensitivity by RCN2 requires active calcineurin. The growth of
wild-type and cnb1∆, vps13∆, and cnb1∆ vps13∆ mutants (a), wild-type, cna1∆, vps13∆, and cna1∆ vps13∆ (b), and wild-type,
cmp2∆, vps13∆, and cmp21∆ vps13∆ mutants (c) transformed with empty vector [-] or vector bearing the RCN2 gene on YPD
and YPD + SDS medium. Plates were incubated for 3 days.
2.4. Both rcn2-m1 and rcn2-m3 Mutations Abolish the Binding of Rcn2 to Catalytic Subunit of
Calcineurin, Cmp2
We noticed that mutations in the rcn2-m3 allele caused changes in the PSITVN se-
quence (aa 256–261) previously identified in the calcineurin binding site, described as
PxIxIT-type [6,9], but did not abolish suppression. To clarify the mechanism by which
RCN2 suppresses vps13∆ mutant phenotypes, we tested the ability of mutant Rcn2 versions
to bind to calcineurin subunits. By using the two-hybrid system, we tested whether we
could detect the binding of Rcn2 to both phosphatase catalytic subunits, Cna1 and Cmp2
and, additionally, to the phosphatase regulatory subunit Cnb1. Using this approach, we
found that Rcn2 bound to Cmp2, but not to Cna1 or Cnb1 (Figure 4a). As a control, we
tested the interaction of Cna1 and Cmp2 with calmodulin (Cmd1), and we observed both
interactions, as expected (Figure S3). The observed lack of interaction of Rcn2 with Cna1
was surprising, so we checked whether the addition of Ca2+ to the medium allowed the
interaction of Rcn2 with Cna1. Indeed, in the presence of Ca2+ and after a long time
(>7 days), the interaction was visible (Figure 4b), suggesting that the interaction of Rcn2
with Cna1 is probably weak and/or controlled. We also found that both Rcn2-m1 and
Rcn2-m3 lost the ability to bind Cmp2 (Figure 4c) while Rcn2-m2 interacted with Cmp2
similarly to wild-type Rcn2. Thus, the interaction of Rcn2 with calcineurin required two
different motifs of Rcn2: one at the N-terminus and the second, the PIxIxIT-type motif
(aa 256–261) at the C-terminus. Moreover, the presence of this last motif alone was not
sufficient to support interaction.
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Figure 4. Rcn2 requires two motifs for the binding of Cmp2, and they are both required to efficiently inhibit calcineurin.
(a) Rcn2 interacts with Cmp2, but not with Cna1 and Cnb1 in the two-hybrid system. (b) Addition of Ca2+ enables the
interaction of Rcn2 with Cna1 in the two-hybrid system. (c) The rcn2-m1 and rcn2-m3 mutations abolished the interaction
of Rcn2 with Cmp2. (d) Calcineurin is activated by calcium, and this effect is abolished by RCN2, but not by rcn2-m1
overexpression. Calcineurin activity was assayed in wild-type cells transformed with empty plasmid [-] or plasmid bearing
the indicated alleles of RCN2, which were grown in standard growth conditions (+ 0 mM Ca2+) or with the addition of
calcium ions (+ 100 mM Ca2+). The graph presents means with error bars indicating SD. Results were analyzed using
two-tailed Student’s t-test (n = 3, p < 0.0005 ***; <0.005 **; <0.05 *; ns, non-significant). (e) Rcn2-S255A interacts with both
Cna1 and Cmp2 in the presence and in the absence of Ca2+.
2.5. Partial Inhibition of Calcineurin Activity is Necessary for Suppression
To better understand the mechanism of vps13∆ suppression by Rcn2, we examined the
influence of RCN2 mutant gene overexpression on calcineurin activity. To compare the activ-
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ity of calcineurin, we used a reporter system that comprised a plasmid containing a CDRE
regulatory element fused to the lacZ open reading frame encoding β-galactosidase [21].
Upon calcineurin activation, the expression of CDRE element-driven sequences is upregu-
lated, for example, in response to an increase in cytoplasmic calcium levels, resulting in an
increased β-galactosidase activity. In our experimental settings, β-galactosidase activity
was measured in cell extracts derived from transformants of the wild-type strain bearing
empty vector or plasmids with different RCN2 alleles. The transformants were grown in the
absence or after the addition of extra calcium ions to induce calcineurin activity. The results
demonstrate that the activity of calcineurin was slightly reduced by the overexpression of
wild-type RCN2 (p < 0.05) with an almost equivalent reduction by the expression of tested
rcn2 versions when cells were grown without the addition of calcium ions to the medium.
As expected, when calcium ions were added to the culture of cells transformed with an
empty vector, calcineurin activity increased (Figure 4d). The overexpression of the RCN2 or
rcn2-m2 allele significantly prevented the activation of calcineurin under these conditions.
The overexpression of the rcn2-m1 allele did not affect calcineurin activity. The effect of the
rcn2-m3 mutation on Rcn2 action was minor compared with that of the rcn2-m1 mutation
but was significant. This indicates that two mutations, rcn2-m1 and rcn2–m3, affect Rcn2
function as a calcineurin inhibitor; thus, at least two motifs in the Rcn2 protein determine
its inhibitory activity toward calcineurin. One is the well-known calcineurin-binding motif
PSITVN (aa 256–261) at the C-terminus. As revealed by studying Rcn2-m1, the second
element that influences Rcn2-binding to calcineurin is found at the N-terminus, and this
last element is necessary for the suppression of vps13∆. Because the rcn2-S255A mutation
also impairs the ability of Rcn2 to suppress vps13∆ and the resulting amino acid residue
substitution is in the calcineurin-binding motif PSITVN (aa 256–261), therefore, we tested
if this influences the interaction with Cna1 and Cmp2 in the presence and in the absence
of Ca2+. Surprisingly, Rcn2-S255A interacted well with both alternative catalytic subunits
(Figure 4e). This result supports the earlier conclusion that inhibition of only Cmp2-based
activity is necessary for suppression.
2.6. Rcn2 Binds to the Cmp2 Fragment Corresponding to aa 382–455
Based on our results, we suspected that a second calcineurin-binding site might be
present in the N-terminus of Rcn2. The Rcn1 inhibitor has two types of calcineurin-binding
sites: the PxIxIT-type and LxVP-type [6]. Even though the calcineurin-binding site of
the LxVP-type is not present in Rcn2, we speculated that Rcn2 might interact using an
N-terminal motif that was inactivated in Rcn2-m1. We noticed that the sequence TQILIT (aa
9–14) in the Rcn2 protein is close to the PxIxIT consensus sequence, with only the P residue
missing. For this reason, we investigated whether Rcn2 binds to the region of calcineurin
catalytic subunits responsible for the binding of substrates. Fragments of Cna1 (Cna1f; aa
340–413) and Cmp2 (Cmp2f; aa 382–455) encompassing the sequence responsible for the
binding of the PxIxIT-type motif (Figure 5a) were tested for interaction with Rcn2 using
the two-hybrid system. The analysis revealed that Rcn2 and Rcn2-m2 and -m3 proteins do
not interact with Cna1f (Figure 5b), but they do interact with Cmp2f, while Rcn2-m1 does
not interact with either (Figure 5c). This result suggests that the N-terminal part of Rcn2
can indeed support binding to calcineurin even when the C-terminal PxIxIT-type motif (aa
256–261) is abolished. The second Cmp2-binding determinant of Rcn2 interacts with this
phosphatase, although its aa sequence does not perfectly fit the consensus. Interestingly,
the C-terminal PxIxIT-type motif of Rcn2 (aa 256–261) is not sufficient to support Cmp2-
binding when the N-terminal motif is absent (rcn2-m1, Figure 5c). This result shows that
the specificity of Rcn2 for binding the Cmp2 phosphatase subunit is maintained even when
only a fragment of this protein is analyzed. In summary, Rcn2 binds a subset of calcineurin
complexes, that is, those containing Cmp2, using two motifs—the already-described PxIxIT-
type motif (aa 256–261) and the newly characterized motif, which encompasses aa 9–14
(TQILIT) at the N-terminus.
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Figure 5. Rcn2 binds to the fragment of Cmp2 involved in the binding of the PXIXIT-type motif in
substrates, but not to an analogous region of Cna1. (a) Schematic presentation of Cna1 and Cmp2
proteins with the indicated fragments (Cna1f; aa 340–413 and Cmp2f; aa 382–455) used to study
interaction with Rcn2. (b) Rcn2 and Cna1f do not interact in the two-hybrid system. (c) Rcn2 and
Cmp2f interact in the two-hybrid system. BD, DNA-binding domain; AD, activating domain.
3. Discussion
Ca2+-ion signaling is fundamental for neuron function. Ca2+ fluxes across the plasma
membrane and between intracellular compartments in response to different stimuli and
calcium regulates several processes, such as neurite outgrowth, synaptogenesis, synaptic
transmission, plasticity and cell survival. Vps13 proteins are also important for neuronal
cell physiology and mutations in VPS13 genes that cause genetic neurodegenerative dis-
orders in humans. Using the yeast model of VPS13-related disorders, we have shown
that calcineurin activity is potentiated in cells lacking the Vps13 protein and that the
calmodulin/calcineurin signaling pathway could be a target for drug intervention in
VPS13-dependent disorders. However, for the effective modulation of calcium signaling
via the inhibition of calcineurin activity, the drug FK506 or the calcium chelator EGTA must
be limited to a very specific concentration [30]. Here, using yeast, we found a different way
to partially reduce the activity of calcineurin in vps13∆ cells and overcome the associated
defects. We demonstrate that this could be achieved by overexpression of the RCN2 gene
encoding Rcn2 protein, a calcineurin inhibitor that binds preferentially to Cmp2, one of
two alternative calcineurin catalytic subunits. Moreover, our studies reveal that binding
between Rcn2 and Cmp2 requires two motifs in Rcn2: the already-known motif at the C-
terminus and the newly characterized motif at the N-terminus. Because the Ca2+ signaling
pathways are preserved from yeast to humans, we assume that our findings may be helpful
for patients suffering from VPS13-dependent diseases or other neurodegenerative diseases
characterized by high calcineurin activity, such as Parkinson’s disease.
Using yeast vps13∆ mutant cells, a model of ChAc and other VPS13-dependent dis-
eases, we demonstrated that calmodulin–calcineurin signaling is a suitable target for drug
intervention [30]. Similarly, for Parkinson’s disease, reduction of calcineurin activity was
shown to mitigate alpha-synuclein toxicity in both yeast and mouse models [29]. Although
drugs that reduce calcineurin activity, such as cyclosporin A and FK506, are known and
have been used for years as immunosuppressants after transplantation, their use has many
side effects on the nervous system, such as recurrent headaches, tremors, seizures, and
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even a decrease in cognitive function or changes in brain structure [8]. These symptoms put
the long-term use of immunosuppressant drugs into question, especially for neurological
disorders. This is also because both insufficient and excessive phosphatase activity has
an adverse effect, as demonstrated in vps13 mutant cells by us [30] or in alpha-synuclein-
producing yeast cells by others [29]. Thus, further research is needed to discover alternative
methods for the reduction of calcineurin activity without causing neurotoxicity, and stud-
ies in yeast can be very helpful [57]. Our multicopy suppressor screen was designed to
find ways to circumvent the effects of the vps13-I2749R mutation, equivalent to a hvps13A-
I2771R mutation found in ChAc patients [47], identified the RCN2 gene encoding a negative
regulator of calcineurin and gave us a hint for further study.
We tested two hypotheses about the molecular mechanism of Rcn2 action in the
vps13∆ mutant. The first hypothesis assumes that overproduced Rcn2 binds and sequesters
Slt2 and that this reduces Slt2 kinase activity toward other substrates, such as the plasma
membrane high-affinity Ca2+ influx system comprising Cch1 and Mid1 proteins. As a
consequence, decreased phosphorylation of the channel reduces its activity and calcium
influx into the cell [27]. Our finding that the overexpression of the rcn2-m2 allele, which
encodes a protein variant unable to bind Slt2, is still able to suppress vps13∆, argues against
this hypothesis. In the same line is the finding that the homologous RCN1 gene, which
encodes the Rcn1 protein and also has potential Slt2-binding sites, did not rescue vps13∆
growth on SDS media. Although the study of the rcn2-S255A allele indicates that the
S255 residue, an acceptor residue for Slt2-dependent phosphorylation, is important for the
suppression of the vps13∆ mutant, it could be modified by another kinase instead. This can
be concluded from the finding that the rcn2-m2 allele, which encodes a protein that is not
able to bind Slt2, is an efficient multicopy suppressor of vps13∆. However, phosphorylation
of residue S255 by unknown kinase is crucial for the regulation of Rcn2 interaction with
alternative catalytic subunits of calcineurin.
The second most probable possibility for the mechanism of the suppression of vps13 is
that Rcn2 simply acts as a negative regulator of calcineurin. In fact, in studying various
rcn2 mutant alleles, we found that the ability to partially inhibit calcineurin is correlated
with suppression. Using genetic analysis, we found that the CNA1 and CNB1 genes
are required for RCN2 suppression of vps13∆ and, importantly, that cmp2∆ alone is a
suppressor of vps13∆. Further analysis showed that Rcn2 interacts preferentially with a
subset of calcineurin complexes, namely, those containing Cmp2 as a catalytic subunit. The
weak interaction with Cna1 was only observed when cells were grown in the presence
of additional Ca2+. This is in contrast to the earlier result of a co-immunoprecipitation
experiment in which Rcn2 was found to interact equally well with both Cna1 and Cmp2
subunits [58]. The selective binding and inhibiting of the Cmp2 catalytic subunit (but
not to Cna1), which is required for suppression, suggests the existence of a difference in
specificity or regulation between Cmp2- and Cna1-containing calcineurin complexes. It
was previously shown that the presence of the CMP2 gene is more important than CNA1
in the ER stress response [59]. It is worth noting that the activity of calcineurin is only
partially inhibited by Rcn2, which is in agreement with the view that it might inhibit
only a subset of calcineurin complexes. The observed selective interaction of Rcn2 with
Cmp2 supports the hypothesis that the selective inhibition of Cmp2-based complexes is
important for the survival of the vps13∆ mutant under stress conditions. This finding is
additionally supported by the fact that Rcn2-S255A, which interacts with Cna1, lost the
ability to suppress. In mammals, it is known that specific catalytic subunits of calcineurin
also differ in their substrate specificity [60] and regulation. For example, it was shown that
for T cell activation, calcineurin activity could be selectively regulated by ubiquitination
and deubiquitination depending on the catalytic subunit [16]. The conclusion, similar to
ours—that different RCANs have the potential to interact and regulate different calcineurin
subunits isoforms—comes from studies in rodents in which three catalytic calcineurin
subunits (CnA)—Aα, Aβ, and Aγ [61–64] have been shown to have different distributions
in the brain corresponding to that of individual RCAN proteins [65]. Moreover, in humans,
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the distribution of calcineurin subunits is tissue-specific, with Aα and Aβ isoforms being
ubiquitously expressed in a variety of tissues and Aγ restricted to the brain and testis [60].
Thus, it is possible that inhibiting one of the calcineurin isoforms in patients suffering from
ChAc or other neurodegenerative diseases may help to overcome pathologies without the
side effects connected to the inhibition of all isoforms by FK506.
The requirement for selective and only partial inhibition of phosphatase activity is also
supported by the fact that RCN1, which encodes the other calcineurin regulator present
in yeast cells, was not isolated in our screen and, when overexpressed, did not suppress
the SDS hypersensitivity of the vps13∆ mutant. In fact, Rcn1 differs from Rcn2 in several
ways. It interacts with Cna1 [6] and has the ability to activate calcineurin [9,66], but, most
importantly, Rcn1 has two different types of calcineurin-binding motifs, the PxIxIT-type
and LxVP-type, while in Rcn2, the LxVP-type motif is missing [58]. The presence of
two phosphatase-interacting motifs in Rcn1 means that the binding is dual. This was
demonstrated for RCAN1 or A238L from the African swine fever virus. Their motifs,
similar to those in NFAT, occupy the PxIxIT-binding site on Cna, and the amino acid chain
then turns back to allow the second motif to encompass the LxVP-binding pocket on the
Cna/Cnb interface [67,68]. We demonstrate here that Rcn2 probably similarly interacts
with Cmp2 using a dual-binding mode. This is suggested by the fact that Rcn-m3 is able to
interact with Cmp2f, but not with Cmp2. Thus, the scenario is that Rcn2 first requires a C-
terminal PSITVN motif (PxIxIT-type; aa 256–261) to bind Cmp2 and then the N-terminally
located second motif. However, the difference is that the second motif in Rcn2 is not
LxVP-like. This suggests that either Rcn2 possesses a structural calcineurin-binding motif
in which part of the interacting surface is located at the C-terminus and the second part
at the N-terminus, or there are two binding sites, and their binding occurs sequentially.
The distinction between these two presented scenarios requires further study. In vitro
studies have indicated that a synthetic peptide derived from the C-terminal part of Rcn2,
the PSITVN motif, effectively competes with the PVIVIT peptide for binding to human
calcineurin [9], which supports the idea of the presence of two independent binding motifs.
This result also suggests that it should be possible to use a peptide derived from the N-
terminal part of yeast Rcn2 to inhibit human calcineurin. Our present work indicates that
this peptide may have a very desirable property. It has the potential for selective inhibition
of only a subset of calcineurin and does not completely block calcineurin activity. For
this reason, it should be less toxic for cells than immunosuppressant drugs such as FK506,
similar to other tested peptides derived from human RCAN or the protein inhibitor A238L
from the African swine fever virus [68].
Our studies are important from a clinical perspective. Here, we show a way to control
calcium signaling more selectively than by the administration of calcineurin chemical
inhibitors. Our present study suggests that new peptides with inhibitory activity toward
calcineurin could be designed as an alternative to those investigated so far [68,69] and be
specific to a subset of calcineurin complexes. Moreover, comparable changes observed on a
molecular level, such as defects in vesicular trafficking, endocytosis, and the actin cytoskele-
ton, and increased calcineurin activity in yeast Parkinson’s alpha-synuclein model [29]
and VPS13-deficiency model [46], which includes early-onset Parkinsonism, suggest that a
similar approach can be taken for the treatment of several diseases.
4. Materials and Methods
4.1. Strains, Media, and Growth Conditions
For cloning and plasmid propagation, E.coli DH5α was used. The yeast strains used in
this study are listed in Table S1 (Table S1). The strains KJK190 and KJK191 were constructed
by integration of the vps13::URA3 cassette amplified by PCR into the genomic DNA of the
KJK181A strain. Strains BYcna1∆ and BYcmp2∆ were transformed with the PCR product,
and transformants were selected on SC-Ura plates. Integrations were confirmed by PCR
of genomic DNA. These strains were used to test the SDS sensitivity phenotype and the
influence of RCN2 overexpression on cell growth.
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The media used were YPD complete medium (1% yeast extract, 2% peptone, 2%
glucose) or synthetic SC medium (0.067% yeast nitrogen base without amino acids, 2%
glucose) with supplements (adenine, uracil, amino acids) as indicated.
For growth tests, transformants were grown overnight in liquid media, and cultures
were diluted to an optical density OD600 of ~1. Five-fold serial dilutions of cells were
spotted on solid YPD with or without the addition of SDS (Sigma-Aldrich, St Louis,
MO, USA) media, as described in the figure legends. Plates were incubated at 30 ◦C.
The sensitivity of vps13∆ mutant cells to SDS is variable and depends on several factors,
such as the medium lot, the lot of the SDS stock solution, and various physical factors;
therefore, in each growth experiment, several SDS concentrations were tested, and one
representative result is shown. For two-hybrid analysis, the PJ69-4A strain [70] was used,
and respective transformants were grown on SC-Trp-Leu plates, replicated on SC-Trp-
Leu-His supplemented with 1.5 mM 3-aminotriazole (Sigma-Aldrich) or SC-Trp-Leu-His
supplemented with 1.5 mM 3-aminotriazole and 25 or 50 mM CaCl2. Plates were incubated
at 30 ◦C for 3–10 days.
4.2. Plasmids, Mutagenesis, and Screen for Multicopy Suppressors of vps13 Mutations
All plasmids used in this study are listed in Table S2. Screening for multicopy sup-
pressors of the vps13-I2749R SDS hypersensitivity phenotype is described in Soczewka et al.
2019 [30]. A plasmid with a DNA fragment containing the RCN2 gene, which was isolated
as a multicopy suppressor from the pFL44-based genome library [71], was used to amplify
RCN2 by PCR. Next, the amplified fragment was transferred to the YEp181lac plasmid [72]
using BamHI and EcoRI restriction enzymes to obtain YEplac181-RCN2.
The SLT2, CNA1, CMP2, and CNB1 genes were amplified by PCR using BY4741
genomic DNA as a template with appropriate primers (Table S3) and were cloned into
pGBT9 and/or pGAD424 vectors. Mutant rcn2-m1, rcn2-m2 and rcn2-m3 alleles were
obtained using one-step mutagenesis with appropriate primers. The construct YEp181lac-
3HA-RCN2 contains a 3HA-tag coding sequence followed by the full-length RCN2 gene.
It is a derivative of the YEp181lac-KXS-RCN2 plasmid in which KpnI (K), XhoI (X), and
SacI (S) restriction sites were introduced directly in front of the RCN2 ATG sequence in
YEp181lac-RCN2 by generating two types of overlapping PCR products (A and B) using
Phusion High Fidelity DNA polymerase and the following pairs of primers. For the type A
product, RCN2_For and L486KXS were used; for the B product, U486KXS and RCN2_Rev
were used. Both products (A and B) were purified and used as templates for the next round
of PCR reactions with the use of RCN2_For and RCN2_Rev primers. The final products
were digested with BamHI and EcoRI, and the restriction fragments were transferred to the
YEplac181-RCN2 plasmid, exchanging the original sequence for the introduced sequence
with KpnI, XhoI, and SacI restriction sites immediately before the ATG codon. The 3HA
encoding sequence was amplified from the plasmid pET9dSUMO [73] with primers 3HA-
U50 and 3HA-L130 flanked by KpnI and SacI restriction sites. The PCR product was
digested with KpnI and SacI and cloned into YEp181lac-KXS-RCN2. All PCR products
were sequenced after cloning.
4.3. β-Galactosidase Activity Assay
β-Galactosidase activity was analyzed as previously described [74]. For this assay,
cells were transformed with the pAMS363 plasmid bearing CDRE-LacZ fusion and either
an empty plasmid or a plasmid bearing one of the RCN2 alleles. Transformants were grown
overnight in SC-Ura-Leu and then diluted and divided into two independent cultures, one
of which was supplemented with CaCl2 to a final concentration of 100 mM. The cells were
grown for another 4 h, and extracts were prepared using glass beads. In each of the three
experiments, at least three independent transformants of the respective yeast strains were
inoculated, and their extracts were assayed in duplicate.
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4.4. Protein Extracts and Western Blot Analysis
Yeast cells were grown at 30 ◦C in SC-Leu to the logarithmic phase. Protein extracts
were prepared by alkaline lysis [75]. Samples were analyzed by standard SDS–PAGE
followed by Western blotting using a mouse monoclonal anti-HA epitope (BioLegend,
San Diego, CA, USA) and Vma2 (Thermo Fisher Scientific, Waltham, MA, USA) or the
polyclonal anti-GAL4 DNA-BD rabbit antibody (Sigma-Aldrich) followed by secondary
anti-mouse or anti-rabbit IgG horseradish peroxidase (HRP)-conjugated antibodies (Dako,
Glostrup, Denmark). The signal was detected by enhanced chemiluminescence (Millipore,
Darmstadt, Germany).
Supplementary Materials: Supplementary Materials can be found at https://www.mdpi.com/1422
-0067/22/3/1193/s1.
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